NDAORALTABLET
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
DELSTRIGO (doravirine, lamivudine, and tenofovir disoproxil fumarate) by Merck & Co. is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2018.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DELSTRIGO is a fixed-dose combination tablet containing doravirine (a non-nucleoside reverse transcriptase inhibitor), lamivudine, and tenofovir disoproxil fumarate for once-daily oral treatment of HIV-1 infection. It works by inhibiting reverse transcriptase, a key enzyme required for HIV replication. The product is indicated for treatment-naïve and treatment-experienced adults with HIV-1.
$0.016BPart D
PeakStable
10.1 years to LOEProduct is in peak lifecycle stage with modest Part D spending; commercial team remains stable but growth opportunities are limited in a mature HIV market.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients
Started Nov 2023
19 enrolled
Hiv
Career Relevance
Working on DELSTRIGO offers career stability in a mature, well-established therapeutic area with predictable commercial dynamics and strong patient populations. Roles focus on maintaining market position, payer negotiations, and physician engagement rather than launch innovation or rapid growth.
Brand Manager
Worked on DELSTRIGO at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.